Dogecoin (DOGE)Trading Volume Jumps to $2.12B as Market Activity Picks Up
The recent increase in Dogecoin trading volume on major exchanges to $2.12 billion in 24 hours is a telling story about the resurgence of interest in the coin, following a period of muted activity in DOGE trading. At press time, DOGE is trading at $0.1424 with an increase of 6.22% over the past 24 hours.
Tweet Highlights DOGE Volume Surge
A recent update on X by the user named dogegod, the recent surge in the coin trading volumes, is declared to be a “bullish sign of higher levels of interest and higher levels of participation.” This social confirmation aligns well with the numerical information presented in this report and suggests that the community is increasingly focused on the coin.
Also Read: Dogecoin (DOGE) Warning: Feb 1 Price Prediction Sparks Speculation
Exchange Data Confirms Increase In Trading
This confirms the rising trend mentioned earlier, as evidenced by the 1-Day Volume Chart on TradingView, which shows yet another spike in volume. The 1-Day Volume figure is $2.229 Billion (or $0.029 Billion higher than the last stated volume of $2.12 Billion).
The volume bars also show a marked increase in trader activity compared to the previous trading sessions, where there was minimal trader activity.
This shows that while trader activity has returned to the market, they are doing so cautiously at this time. Therefore, there is likely to be a degree of price fluctuations for Dogecoin during the immediate future, due to the growing interest in the coin.
The sharp increase in the coin’s Trading Volume suggests that there is renewed interest in the coin. Even though Dogecoin’s price remains below major moving averages, renewed exchange activity and heightened interest from the community suggest that Dogecoin will be one of the cryptocurrencies we will be watching very closely over the near term.
Also Read: Dogecoin (DOGE) Enters Major Accumulation Phase Charts Point to Rally Toward $0.75
You May Also Like
CEO Sandeep Nailwal Shared Highlights About RWA on Polygon
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
